Cargando…

Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review

The efficacy of vortioxetine has been proven in many studies, but data concerning discontinuation symptoms (DS) after vortioxetine withdrawal is scarce. The aim of our study is to systematically evaluate the prevalence, determinants, and clinical features of vortioxetine DS in a retrospective chart...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siwek, Marcin, Chrobak, Adrian Andrzej, Gorostowicz, Aleksandra, Krupa, Anna Julia, Dudek, Dominika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151377/ https://www.ncbi.nlm.nih.gov/pubmed/34064611 http://dx.doi.org/10.3390/ph14050451

Ejemplares similares

Lurasidone Augmentation of Clozapine in Schizophrenia—Retrospective Chart Review
por: Siwek, Marcin, et al.
Publicado: (2023)

Case Report: Vortioxetine in the Treatment of Depressive Symptoms in Patients With Epilepsy—Case Series
por: Siwek, Marcin, et al.
Publicado: (2022)

TED—Trazodone Efficacy in Depression: A Naturalistic Study on the Efficacy of Trazodone in an Extended-Release Formulation Compared to SSRIs in Patients with a Depressive Episode—Preliminary Report
por: Siwek, Marcin, et al.
Publicado: (2023)

TED—trazodone effectiveness in depression: a naturalistic study of the effeciveness of trazodone in extended release formulation compared to SSRIs in patients with a major depressive disorder
por: Dudek, Dominika, et al.
Publicado: (2023)

Polish adaptation of the Dimensional Anhedonia Rating Scale (DARS) - validation in the clinical sample
por: Gorostowicz, Aleksandra, et al.
Publicado: (2023)

Unprescribed and unnoticed: Retrospective chart review of adverse events of interactions between antidepressants and over-the-counter drugs
por: Woroń, Jarosław, et al.
Publicado: (2022)

Harder, better, faster, stronger? Retrospective chart review of adverse events of interactions between adaptogens and antidepressant drugs
por: Siwek, Marcin, et al.
Publicado: (2023)

Graph Analysis of Verbal Fluency Tests in Schizophrenia and Bipolar Disorder
por: Chrobak, Adrian Andrzej, et al.
Publicado: (2022)

When practice does not make a perfect - paradoxical learning curve in schizophrenia and bipolar disorder revealed by different serial reaction time task variants
por: Chrobak, Adrian Andrzej, et al.
Publicado: (2023)

Lurasidone in Therapy of Treatment-resistant Ultra-rapid Cycling Bipolar Disorder: Case Report
por: Siwek, Marcin, et al.
Publicado: (2021)

Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders
por: Siwek, Marcin, et al.
Publicado: (2023)

Altered Functional Connectivity Differences in Salience Network as a Neuromarker of Suicide Risk in Euthymic Bipolar Disorder Patients
por: Sobczak, Anna Maria, et al.
Publicado: (2020)

Clozapine discontinuation withdrawal symptoms in schizophrenia
por: Blackman, Graham, et al.
Publicado: (2021)

Psychopharmacology and Biological Studies of Psychosis
por: Siwek, Marcin, et al.
Publicado: (2023)

Time-Frequency Characterization of Resting Brain in Bipolar Disorder during Euthymia—A Preliminary Study
por: Chrobak, Adrian Andrzej, et al.
Publicado: (2021)

Depressogenic medications and other risk factors for depression among Polish patients with epilepsy
por: Bosak, Magdalena, et al.
Publicado: (2015)

Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation—Is It Feasible to Develop Evidence-Based Guidelines?
por: Blackman, Graham, et al.
Publicado: (2021)

Machine Learning-Based Identification of Suicidal Risk in Patients With Schizophrenia Using Multi-Level Resting-State fMRI Features
por: Bohaterewicz, Bartosz, et al.
Publicado: (2021)

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
por: De Berardis, Domenico, et al.
Publicado: (2020)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

Dopamine agonist withdrawal syndrome associated factors: A retrospective chart review
por: Garcia, Xiomara, et al.
Publicado: (2022)

Conversations with clients about antidepressant withdrawal and discontinuation
por: Karter, Justin M.
Publicado: (2020)

The Biological Rhythms Interview of Assessment in Neuropsychiatry in patients with bipolar disorder: correlation with affective temperaments and schizotypy
por: Dopierala, Ewa, et al.
Publicado: (2016)

Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?
por: Okada, Fumihiko
Publicado: (2007)

Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation
por: Fluyau, Dimy, et al.
Publicado: (2018)

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
por: Chen, Grace, et al.
Publicado: (2017)

Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients
por: Findling, Robert L., et al.
Publicado: (2017)

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

Clinical effectiveness of vortioxetine in postcovid syndrome
por: Vikarenko, M., et al.
Publicado: (2022)

Determinants of success of loading dose diazepam for alcohol withdrawal: A chart review
por: Bharadwaj, Balaji, et al.
Publicado: (2012)

Frequency of and factors associated with antiseizure medication discontinuation discussions and decisions in patients with epilepsy: A multicenter retrospective chart review
por: Terman, Samuel W., et al.
Publicado: (2023)

Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes
por: Di Nicola, Marco, et al.
Publicado: (2023)

Crystal structures of vortioxetine and its methanol monosolvate
por: Zhou, Xin-Bo, et al.
Publicado: (2015)

Which Cognitive Domains are Improved by Treatment with Vortioxetine?
por: Harrison, John E, et al.
Publicado: (2016)

Vortioxetine improves cognition in mild cognitive impairment
por: Tan, Sheng Neng, et al.
Publicado: (2021)

RisksAssociated with Vortioxetine in the Established Therapeutic Indication
por: Verma, Akansha, et al.
Publicado: (2021)

Vortioxetine Improved Depressive State In Parkinson’s Disease
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Potential Effect of Vortioxetine on Restless Leg Syndrome
por: Alıcı, Yasemin Hoşgören, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vmsmuc4nc4ehmk5db5g3goqhfo